Good MorningEquities markets began the day in the green on Thursday but reversed course later. The combined impact of rising oil prices and hawkish Fed-Speak sapped bullish sentiment and drove the S&P 500 down more than 1.0%. Oil prices climbed 2.5% despite easing sanctions on Venezuela. The news is good, but it will be years before Venezuela's oil infrastructure can support large-scale production. WTI has confirmed support at a key level and will likely move higher and underpin inflation.
In other news, Fed chief Jerome Powell says inflation is still too high. In his view, economic growth may have to slow for inflation to hit the 2% target, meaning high rates will be here indefinitely. The risk now is that oil prices will keep the Fed on the brakes, leading to another interest rate hike. In this scenario, more banks fail, and economic slowing could result in a full-blown recession. As it is, the US is only expected to grow by 1.5%, which is far less than the pace of inflation. Featured: Forget Nvidia, This “Ghost Town” Company Holds the Key to the AI Boom (Ad) 
|
Markets | | |
Today's market is not the one you inherited many years ago; this is entirely different. With giants like BlackRock (NYSE: BLK) and The Goldman Sachs Group (NYSE: GS) guiding their own ships toward a mix of yield and liquidity and away from what seems to be overvalued stocks, you, too, can adjust a... Read the Full Story |
|
From Our Partners | | Tesla's About to Prove Everyone Wrong... Again
Back in 2018, when Jeff Brown told everyone to buy Tesla…
The "experts" said Elon was finished and Tesla was headed for bankruptcy.
Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough. | | Click here to see why Tesla's about to prove everyone wrong... again. |
|
Markets | | |
Shares of Adobe Inc. (NASDAQ: ADBE) are forming a flat base with a 13% correction beneath a September 8 high of $570.24.
While many stocks have tumbled as AI optimism is taking a breather, Adobe has held up. The S&P 500 component is outperforming the S&P 500 by a wide margin on both... Read the Full Story |
|
Stocks | | |
The post-pandemic revenge travel boom may be winding down, at least depending on which company you ask.
Revenge travel refers to the boom that occurred as Covid restrictions eased and people rebooked canceled travel plans and took advantage of their freedom to move around again.
Shar... Read the Full Story |
|
From Our Partners | | A Historic Gold Announcement Is About to Rock Wall Street?
For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time could validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains. | | Click here to get Garrett’s Top Four picks now. |
|
Stocks | | |
Since October 5, gold prices have been doing what they tend to do: Rise amid economic and geopolitical uncertainties. That’s why so many investors consider gold either a safe haven or a hedge against falling stock prices.
Gold miners Alamos Gold Inc. (NYSE: AGI) and Gold Fields Limited (NYS... Read the Full Story |
|
Stocks | | | Wall Street racked up more losses Friday to close out its worst week in a month.The S&P 500 fell 1.3% for a fourth straight drop. The Dow Jones Industrial Average sank 286 points, or 0.9%, and the Nasdaq composite tumbled 1.5%.The stock market has been struggling under the weight of the bond mar... Read the Full Story |
|
From Our Partners | | The Tesla Shock Nobody Sees Coming
While headlines scream "Tesla is doomed"...
Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs.
One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as July 23rd. | | Click here to see the Tesla shock that could blindside everyone. |
|
Markets | | | CSX reported a 24% drop in the railroad's third-quarter profit Thursday as it hauled 2% less freight, but the CEO said customers are noticing that its trains are running more smoothly.The Jacksonville, Florida-based railroad said it earned $846 million, or 42 cents per share, in the quarter. That's ... Read the Full Story |
|
Markets | | | Federal Reserve Chair Jerome Powell said Thursday that inflation remains too high and that bringing it down to the Fed's target level will likely require a slower-growing economy and job market.Powell noted that inflation has cooled significantly from a year ago. But he cautioned that the economy is... Read the Full Story |
|
Markets | | | Union Pacific's third-quarter profit fell 19% as the railroad hauled about 3% fewer shipments and costs remained high, but the average speed of its trains improved 5% as new CEO Jim Vena began to tweak the operations Read the Full Story |
|
Markets | | | The Justice Department has secured a $9 million settlement with Ameris Bank over allegations it avoided underwriting mortgages in predominately Black and Latino communities in Jacksonville, Florida, and discouraged people there from getting home loans Read the Full Story |
|
Markets | | |
Netflix, Inc. (NASDAQ: NFLX) stock shot up more than 16% in midday trading the day after it reported blockbuster earnings. But after rocketing past its 200-day and 50-day simple moving averages, is there still room for investors to get involved with NFLX stock?
The streaming giant added nea... Read the Full Story |
|
Friday's Early Bird Stock Of The Day Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts. | | View Today's Stock Pick |
|
